Research map: Clinical efficacy and safety profile of long-acting lipoglycopeptides versus daily intravenous antibiotics for acute bacterial skin and skin structure infections (ABSSSI): a retrospective study in Greece

Back to the article

Papers in this map

  1. Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection · Helen W. Boucher · 2014 · 436 citations · Cited by this paper
  2. The impact of low-volume hydration on kidney function in low-dose cisplatin therapy for biliary tract cancer: a multicentre retrospective cohort study · 2026 · Related
  3. Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections · L. E. Jauregui · 2005 · 313 citations · Cited by this paper
  4. Pharmacokinetic/pharmacodynamic optimization of antimicrobial therapy in neutropenic sepsis: a comprehensive review · 2026 · Related
  5. Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections · G. Ralph Corey · 2014 · 310 citations · Cited by this paper
  6. Successful remdesivir treatment of coronavirus OC43 pneumonia in a lung transplant recipient · 2025 · Related
  7. Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study · G. Ralph Corey · 2014 · 224 citations · Cited by this paper
  8. A Phase 1 study of abemaciclib plus abiraterone in Japanese patients with metastatic castration-resistant prostate cancer · 2025 · Related
  9. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection · Michael W. Dunne · 2015 · 219 citations · Cited by this paper
  10. A 1:1:1 propensity score matching design to account for center-specific antimicrobial treatment or prophylaxis in observational studies: the case of the POSACOVID study · 2026 · Related
  11. Staphylococcus aureus Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies · Jonah Clegg · 2021 · 179 citations · Cited by this paper
  12. Striking effectiveness of siltuximab-based treatment in refractory idiopathic multicentric Castleman disease resembling IgG4-related disease · 2025 · Related
  13. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen · Brian J. Werth · 2017 · 105 citations · Cited by this paper
  14. The role of gut microbiome in chemoresistance property development in colorectal cancer tissue and its novel therapeutic strategies · 2026 · Related
  15. Antistaphylococcal Activity of Dalbavancin, an Experimental Glycopeptide · Gengrong Lin · 2005 · 91 citations · Cited by this paper
  16. The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study · 2025 · Related
  17. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis · Rajender K. Agarwal · 2017 · 77 citations · Cited by this paper
  18. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections · Javier Fernández · 2016 · 69 citations · Cited by this paper
  19. Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel · Éric Senneville · 2023 · 59 citations · Cited by this paper
  20. New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides · Matthew P. Crotty · 2016 · 50 citations · Cited by this paper
  21. Dalbavancin for Treatment of Staphylococcus aureus Bacteremia · Nicholas Turner · 2025 · 50 citations · Cited by this paper
  22. Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study · Nicholas W. Van Hise · 2020 · 46 citations · Cited by this paper
  23. Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy · Axel A Vazquez Deida · 2020 · 39 citations · Cited by this paper
  24. Therapeutic drug monitoring of antibiotics for methicillin-resistant Staphylococcus aureus infections: an updated narrative review for clinicians · Valentina Galfo · 2024 · 32 citations · Cited by this paper
  25. A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis · Gabriele Maria Leanza · 2024 · 30 citations · Cited by this paper
  26. Efficacy and clinical potential of phage therapy in treating methicillin-resistant Staphylococcus aureus (MRSA) infections: A review · Jamil Allen G. Fortaleza · 2024 · 28 citations · Cited by this paper
  27. The Clinical Efficacy of Multidose Oritavancin: A Systematic Review · Giammarco Baiardi · 2023 · 28 citations · Cited by this paper
  28. The risk of drug resistance during long-acting antimicrobial therapy · Anjalika A Nande · 2022 · 19 citations · Cited by this paper
  29. Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials · Pedro González · 2021 · 15 citations · Cited by this paper
  30. New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides · Valentina Siciliano · 2024 · 13 citations · Cited by this paper
  31. Long-term oritavancin therapy for shoulder prosthetic joint infection: A case guided by therapeutic drug monitoring (TDM) · Antonio Riccardo Buonomo · 2024 · 10 citations · Cited by this paper
  32. The role of long-acting antibiotics in the clinical practice: a narrative review · Giulia Micheli · 2023 · 9 citations · Cited by this paper
  33. Vancomycin, Daptomycin, Antistaphylococcal β-Lactam, and Trimethoprim-Sulfamethoxazole Monotherapy and Combination Therapy in the Management of Methicillin-Resistant Staphylococcus aureus: A Network Meta-Analysis · Xiaonan Xu · 2022 · 8 citations · Cited by this paper
  34. Oritavancin a Therapeutic Option for Periprosthetic Joint Infections in Selected Cases: A Comprehensive Review · Rareş Mircea Bîrluţiu · 2025 · 8 citations · Cited by this paper
  35. Long-Acting Antibiotics: New Opportunities Beyond Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)! · Emanuele Pontali · 2025 · 7 citations · Cited by this paper
  36. A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges? · Maytham H. Hussein · 2025 · 7 citations · Cited by this paper
  37. Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series · Valeria Garbo · 2024 · 6 citations · Cited by this paper
  38. Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin/Soft Tissue and Other Difficult-to-Treat Infections · Giustino Parruti · 2024 · 6 citations · Cited by this paper
  39. Oritavancin for the Treatment of Staphylococcus aureus Bacteremia—A Retrospective Single-arm Cohort Study · H Jordan · 2025 · 6 citations · Cited by this paper

Source: OpenAlex (CC0)